The Incidence and Care Cascade of the Hepatitis C Virus in Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: The 2030 hepatitis C virus (HCV) elimination targets of the World Health Organization are an 80% reduction in incidence and 65% reduction in mortality compared to the 2015 rates. However, information on the nationwide incidence and treatment rates of HCV infection are limited. We aimed to investigate the nationwide incidence and status of the care cascade for HCV infection in Korea. Methods: This study used data from the Korea Disease Control and Prevention Agency linked with the data of the Korea National Health Insurance Service. Linkage to care was defined as visiting hospitals twice or more due to HCV infection within 1.5 years of the index date. The treatment rate was the number who had been prescribed antiviral medication within 1.5 years from the index date out of patients newly diagnosed with HCV. Results: The new HCV infection rate was 17.2 per 100,000 person-years (n=8,810) in 2019. The number of new HCV infections was the highest in patients aged 50 to 59 years (n=2,480), and the new HCV infection rate significantly increased with age (p<0.001). Among newly infected patients with HCV, the linkage to care rate was 78.2% (78.2% men, 78.2% women) and the treatment rate was 58.1% (56.8% men, 59.3% women) within 1.5 years. Conclusions: The new HCV infection rate was 17.2 per 100,000 person-years in Korea. It is necessary to continuously monitor the incidence and care cascade of HCV to establish proper strategies to reach the goal of HCV elimination by 2030.
Abstract
Background/Aims: The 2030 hepatitis C virus (HCV) elimination targets of the World Health Organization are an 80% reduction in incidence and 65% reduction in mortality compared to the 2015 rates. However, information on the nationwide incidence and treatment rates of HCV infection are limited. We aimed to investigate the nationwide incidence and status of the care cascade for HCV infection in Korea. Methods: This study used data from the Korea Disease Control and Prevention Agency linked with the data of the Korea National Health Insurance Service. Linkage to care was defined as visiting hospitals twice or more due to HCV infection within 1.5 years of the index date. The treatment rate was the number who had been prescribed antiviral medication within 1.5 years from the index date out of patients newly diagnosed with HCV. Results: The new HCV infection rate was 17.2 per 100,000 person-years (n=8,810) in 2019. The number of new HCV infections was the highest in patients aged 50 to 59 years (n=2,480), and the new HCV infection rate significantly increased with age (p<0.001). Among newly infected patients with HCV, the linkage to care rate was 78.2% (78.2% men, 78.2% women) and the treatment rate was 58.1% (56.8% men, 59.3% women) within 1.5 years. Conclusions: The new HCV infection rate was 17.2 per 100,000 person-years in Korea. It is necessary to continuously monitor the incidence and care cascade of HCV to establish proper strategies to reach the goal of HCV elimination by 2030.
참고문헌 (16)
- Westbrook RH, "Natural history of hepatitis C", J Hepatol, 61(1 Suppl), pp.S58~S68 (2014)
- Maasoumy B, "Natural history of acute and chronic hepatitis C", Best Pract Res Clin Gastroenterol, 26, pp.401~412 (2012)
- Petruzziello A, "Global epidemiology of hepatitis C virus infection : an up-date of the distribution and circulation of hepatitis C virus genotypes", World J Gastroenterol, 22, pp.7824~7840 (2016)
- "Combating Hepatitis B and C to reach elimination by 2030" (2016)[URL]
- 조병욱, "Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study", Clinical and Molecular Hepatology, 23(1), pp.51~56 (2017), 대한간학회[DOI]
- Kwon JH, "Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens : a multicenter study in Korea", J Med Virol, 91, pp.1104~1111 (2019)
- Youn Jae Lee, "An integrated analysis of elbasvir", grazoprevir in Korean patients with hepatitis C virus genotype 1b infection, 2019, pp.25(4), 400~407[DOI]
- Choi Jonggi, "The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment", Gut and Liver, 16(6), pp.964~975 (2022), 거트앤리버 소화기연관학회협의회[DOI]
- McGowan CE, "Barriers to hepatitis C treatment", Liver Int, 32(Suppl 1), pp.151~156 (2012)
- Ryerson AB, "Vital signs : newly reported acute and chronic hepatitis C cases : United States, 2009-2018", MMWR Morb Mortal Wkly Rep, 69, pp.399~404 (2020)
- Ko K, "Epidemiology of viral hepatitis C : road to elimination in Japan", Glob Health Med, 3, pp.262~269 (2021)
- "HCV epidemiology in the United States" (2021)[URL]
- Joon Yeul Nam, "Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study", Gut and Liver, 14(2), pp.207~217 (2020), 거트앤리버 소화기연관학회협의회
- Jang ES, "The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015", Hepatol Int, 13, pp.599~608 (2019)
- Polaris Observatory HCV Collaborators, "Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020 : a modelling study", Lancet Gastroenterol Hepatol, 7, pp.396~415 (2022)
- Kyung-Ah Kim, "Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey", Gut and Liver, 14(5), pp.644~651 (2020), 거트앤리버 소화기연관학회협의회[DOI]